Japanese Sosei Group’s wholly owned subsidiary Heptares Therapeutics has formed a new drug research and development (R&D) collaboration with Imperial College London, UK.

During the multi-year partnership, the firms will work together to accelerate discovery and translational research on new and existing G protein-coupled receptor (GPCR) disease target opportunities for gastro-intestinal (GI) tract.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

With a focus on modulating these GPCRs, the project will support the use of Heptares structure-based methods to develop new treatments for GI conditions, including inflammatory bowel disease.

Sosei Group and Heptares Therapeutics chief R&D officer Malcolm Weir said: “This collaboration with Imperial College London builds on existing GPCR programmes implicated in immune disorders and GI function and we are excited by the potential it offers to support the identification and translation of new therapies for patients with GI diseases.”

“This research will build on the growing body of knowledge around these key membrane receptors in the gut, investigating their potential in therapeutic interventions.”

Heptares will sponsor and support different programmes of the collaboration through target discovery and validation, and will carry out the advancement and commercialisation of any related compounds.

The R&D alliance is also set to support ongoing discovery and development programmes at Sosei and Heptares.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Imperial College London Nutrition and Food Network head professor Gary Frost said: “This research will build on the growing body of knowledge around these key membrane receptors in the gut, investigating their potential in therapeutic interventions.

“We hope this new collaboration with Heptares will enable us to uncover new druggable targets and develop new treatments, which could have far-reaching impact for patients with GI conditions.”